Our research activities are directed towards four key areas:
1. Discovering new molecular targets and disease pathways
2. Developing preclinical models of human disease
3. Establishing and developing evidence in humans
4. Increasing the availability of cannabinoid treatments for patients
Novel clinical research conducted by the Lambert Initiative’s clinical team and collaborators within Australia
An emerging role for cannabinoids in the treatment of addictions
The ability of cannabinoids such as cannabidiol (CBD) to reduce anxiety, prevent seizures and reduce psychotic behaviour may be relevant in the treatment of addiction to alcohol and other drugs
Cannabis use in the community
<p>Understanding the risks related to driving and medical cannabis use</p>
As medical cannabis becomes more readily available, it is imperative that we answer questions around the risks. Our research is contributing to the ongoing policy debate regarding issues such as safety, impairment and detection when driving.
Developing the next generation of cannabinoids
Our medicinal chemistry team are synthesising innovative libraries of cannabinoid molecules to discover and develop new clinical candidates with improved therapeutic properties.
Medicinal cannabis and the treatment of chronic pain
The Lambert Initiative is researching the application of phytocannabinoids to assist in the treatment and management of chronic and neuropathic pain.
Surveys are a valuable method of data collection, and are incredibly useful in providing snapshots of information via questions put to a community.
Cannabinoids and Anxiety
Anxiety disorders are extremely common in the Australian youth population, and there is a large number of young people being left untreated. Not only do these untreated people with anxiety disorders have to struggle with their symptoms, they may also develop secondary conditions such as depression and substance abuse disorders. With the massive surge in anxiety and other mental health conditions around the world in response to the impact of COVID-19, there is a need for new treatment options more than ever.
Cannabinoids and paediatric epilepsy
Katelyn Lambert suffers from Dravet syndrome, a severe form of childhood epilepsy unresponsive to current anticonvulsant drugs. We’re developing cannabinoid medicines to reduce seizures, mortality and intellectual disability.
The importance of cannabis research
Medical cannabis and PTSD
Cannabinoids as sleep-promoters
The therapeutic possibilities of cannabinoids and Tourette Syndrome
Using powerful computation and artificial intelligence to help us understand how cannabinoids work
With computational modelling, we can simulate the molecular interactions between cannabinoids and receptors to gain insight into their physiological activity and expand their therapeutic applications.